SETTING: Lilongwe District, Malawi. OBJECTIVE: To assess the cost and cost-effectiveness of new treatment strategies for new pulmonary tuberculosis patients, introduced in 1997. METHODS: For new smear-positive pulmonary patients, two strategies were compared: 1) the strategy used until the end of October 1997, involving 2 months of hospitalisation at the beginning of treatment, and 2) a new decentralised strategy introduced in November 1997, in which patients were given the choice of in- or outpatient care during the first 2 months of treatment. For new smear-negative pulmonary patients, the two strategies compared were 1) the strategy used until the end of October 1997, which did not require any direct observation of treatment (DOT) and 2) a new community-based strategy introduced in November 1997, which required DOT by a community member 'guardian' or a health worker for the first 2 months of treatment. Costs were analysed from the perspective of health services, patients, and the community in 1998 US dollars, using standard methods. Cost-effectiveness was calculated as the cost per patient cured (smear-positive cases) and as the cost per patient completing treatment (new smear-negative cases). FINDINGS: For new smear-positive patients, the cost per patient treated was dollars 456 with the conventional hospital-based strategy, and dollars 106 with the new decentralised strategy. Costs fell by 54% for health services and 58% for patients. The cost per patient cured was dollars 787 for the conventional hospital-based strategy, and dollars 296 for decentralised treatment. For smear-negative patients, the cost per patient treated was dollars 67 with the conventional unsupervised strategy, and dollars 101 with the community-based DOT strategy. Costs increased for health services, patients and guardians. Cost-effectiveness was similar with both strategies, at around dollars 200 per patient completing treatment. When new smear-positive and new smear-negative patients were considered together, the new strategies were associated with a 50% reduction in total annual costs. CONCLUSION: There is a strong economic case for expansion of decentralisation and community-based DOT in Malawi. Further investment in training and programme supervision may help to increase effectiveness.
SETTING: Lilongwe District, Malawi. OBJECTIVE: To assess the cost and cost-effectiveness of new treatment strategies for new pulmonary tuberculosispatients, introduced in 1997. METHODS: For new smear-positive pulmonary patients, two strategies were compared: 1) the strategy used until the end of October 1997, involving 2 months of hospitalisation at the beginning of treatment, and 2) a new decentralised strategy introduced in November 1997, in which patients were given the choice of in- or outpatient care during the first 2 months of treatment. For new smear-negative pulmonary patients, the two strategies compared were 1) the strategy used until the end of October 1997, which did not require any direct observation of treatment (DOT) and 2) a new community-based strategy introduced in November 1997, which required DOT by a community member 'guardian' or a health worker for the first 2 months of treatment. Costs were analysed from the perspective of health services, patients, and the community in 1998 US dollars, using standard methods. Cost-effectiveness was calculated as the cost per patient cured (smear-positive cases) and as the cost per patient completing treatment (new smear-negative cases). FINDINGS: For new smear-positive patients, the cost per patient treated was dollars 456 with the conventional hospital-based strategy, and dollars 106 with the new decentralised strategy. Costs fell by 54% for health services and 58% for patients. The cost per patient cured was dollars 787 for the conventional hospital-based strategy, and dollars 296 for decentralised treatment. For smear-negative patients, the cost per patient treated was dollars 67 with the conventional unsupervised strategy, and dollars 101 with the community-based DOT strategy. Costs increased for health services, patients and guardians. Cost-effectiveness was similar with both strategies, at around dollars 200 per patient completing treatment. When new smear-positive and new smear-negative patients were considered together, the new strategies were associated with a 50% reduction in total annual costs. CONCLUSION: There is a strong economic case for expansion of decentralisation and community-based DOT in Malawi. Further investment in training and programme supervision may help to increase effectiveness.
Authors: Olivia Oxlade; Judyth Vaca; Elizabeth Romero; Kevin Schwartzman; Brian Graham; Lucero Hernandez; Terry Tannenbaum; Dick Menzies Journal: Can J Public Health Date: 2006 Jan-Feb
Authors: Teralynn Ludwick; Alison Morgan; Sumit Kane; Margaret Kelaher; Barbara McPake Journal: Health Policy Plan Date: 2020-10-01 Impact factor: 3.344
Authors: Francesco Marinucci; Tsegahun Manyazewal; Antonio D Paterniti; Sandra Medina-Moreno; Matthew Wattleworth; Juliana Hagembe; Robert R Redfield Journal: Am J Trop Med Hyg Date: 2013-01-16 Impact factor: 2.345
Authors: Julia R Kemp; Gillian Mann; Bertha Nhlema Simwaka; Felix Ml Salaniponi; Stephen Bertel Squire Journal: Bull World Health Organ Date: 2007-08 Impact factor: 9.408
Authors: Hassan Yekrang Sis; Ali Jannati; Mohammad AsghariJafarabadi; Mohammad Ebrahimi-Kalan; Asghar Taheri; Ahmad Koosha Journal: Health Promot Perspect Date: 2014-07-12